SIRT1 and Lnc-OC1 Expression in Breast and Colorectal Cancers

The SIRT1 gene is involved in many physiological activities of the body, including inflammation, innate and acquired immune system responses, neurodegeneration, age-related disorders, life-span extension, obesity, and heart disease. But its role in cancer is not yet fully understood. Considering the possible role of Lnc-OC1 in the regulation of SIRT1 and tumorigenesis, this study was designed and performed to evaluate the expression of SIRT1 and Lnc-OC1 genes in patients with breast and colorectal cancer.

In this case-control study, during September 2018 to July 2021, 84 patients (47.61%≤60 years, 52.38 >60 years) with breast cancer and 59 patients (42.37% ≤ 60 years, 57.62> 60 years) with colorectal cancer confirmed by pathological findings and the expression of SIRT1 and Lnc-OC1 were assessed using Quantitative real-time PCR.

In colorectal cancer, it appears that increasing the expression of Lnc-OC1, decreased the expression of SIRT1. The expression of Lnc-OC1 gene in patients with breast and colorectal cancer has increased compared to normal tissue. The expression of SIRT1 in patients with breast cancer increased significantly compared to normal tissues, but decreased in patients with colorectal cancer.

The results showed that Lnc-OC1 could be used as an early diagnosis for colorectal cancer by reducing SIRT expression, and the expression of these two genes could be used to assess the prognosis for breast cancer.